Biotech Analysis

Medarex, Mass Biologic License Antibodies to Merck in Deal Worth up to $225M
A combination of monoclonal antibodies co-developed by Medarex Inc. and Massachusetts Biologic Laboratories have been licensed to drug giant Merck & Co. Inc. in a deal worth up to $225M. Medarex and Massachusetts Biologic Laboratories will split equally a $60 million up-front [...]

Discovery Labs Shares Fall on FDA Delay of Surfaxin
Shares in Discovery Labs spiraled downward 52 percent Monday on news that the FDA has again delayed a decision on the company’s application to market Surfaxin for the prevention of respiratory distress syndrome in premature infants. For the fourth time, the agency has issued a complete [...]